Skip to main content

Table 3 Multivariate testing: OR (95% CI) to the first quartile of biomarkers investigated vs stroke lesion site (anterior vs posterior) & stroke lesion dimensions

From: Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?

Variable (Units) / Quartiles

Site

D1

D2

D3

D4

(OR; 95% CI)

(OR; 95% CI)

(OR; 95% CI)

(OR; 95% CI)

(OR; 95% CI)

ESR (mm)

     

Q1 (< 10) n = 23

1

1

1

1

1

Q2 [10 – 16) n = 30

0.650 (0.212-1.993)

0.473 (0.149-1.501)

2.115 (0.666-6.715)

2.625 (0.478-14.428)

7.981 (0.383-166.240)

Q3 [16 – 30) n = 19

0.758 (0.218-2.632)

0.945 (0.277-3-230)

1.319 (0.380-4.577)

2.800 (0.452-17.318)

6.714 (0.283-159.527)

Q4 [> 30) n = 27

1.040 (0.339-3.190)

0.765 (0.246-2.381)

1.538 (0.488-4.853)

5.250 (1.002-27.514)*

0.855 (0.015-48-430)

Fibrinogen (mg/dL)

     

Q1 (< 303) n = 24

1

1

1

1

1

Q2 [303 – 368) n = 25

1.333 (0.415-4.281)

1.366 (0.411-4.539)

0.708 (0.203-2.470)

2.750 (0.479-15.794)

0.958 (0.057-16.243)

Q3 [368 – 462) n = 24

0.824 (0.242-2.797)

1.214 (0.358-4.124)

0.667 (0.190-2.338)

5.500 (1.027-29.451)*

2.091 (0.177-24.734)

Q4 [> 462) n = 25

2.167 (0.682-6.883)

1.619 (0.493-5.319)

0.500 (0.147-1.697)

4.278 (0.789-23.193)

2.000 (0.169-23.623)

Platelets (value x 10.e3/uL)

     

Q1 (< 189) n = 25

1

1

1

1

1

Q2 [189 – 256) n = 25

0.434 (0.138-1.371)

0.826 (0.246-2.776)

1.000 (0.291-3.437)

1.000 (0.278-3.598)

13.683 (0.674-277.964)

Q3 [256 – 323) n = 25

0.519 (0.167-1.611)

1.417 (0.444-4.521)

0.583 (0.178-1.906)

0.059 (0.003-1.175)*

3.122 (0.114-85.732)

Q4 [> 323) n = 25

1.000 (0.330-3.033)

1.962 (0.621-6.193)

0.495 (0.153-1.606)

2.032 (0.608-6.797)

1.000 (0.018-56.631)

Blood Albumin (g/dL)

     

Q1 (< 2.9) n = 25

1

1

1

1

1

Q2 [2.9 – 3.4) n = 24

1.504 (0.488-4.639)

3.150 (0.815-12.168)

0.227 (0.053-0.981)*

1.059 (0.306-3.658)

5.677 (0.243-132.298)

Q3 [3.4 – 3.8) n = 22

1.273 (0.403-4-19)

5.250 (1.351-20.396)*

0.164 (0.038-0.711)*

0.406 (0.091-1.817)

3.558 (0.129-98.252)

Q4 [> 3.8) n = 25

0.402 (0.102-1.349)

3.500 (0.921-13-307)

0.205 (0.048-0.870)*

0.643 (0.173-2.388)

7.933 (0.366-172.044)

Triglycerides (mg/dL)

     

Q1 (< 78) n = 25

1

1

1

1

1

Q2 [78 – 111) n = 26

2.844 (0.913-8.861)

1.474 (0.398-5.452)

0.833 (0.218-3.179)

0.273 (0.072-1.034)

0.958 (0.124-7.383)

Q3 [111 – 162) n = 26

1.778 (0.579-5.457)

9.000 (2.487-32.567)*

0.132 (0.037-0.471)*

0.273 (0.072-1.034)

0.460 (0.039-5.418)

Q4 [> 162) n = 26

0.323 (0.084-1.237)

1.474 (0.398-5.454)

0.679 (0.183-2.510)

0.273 (0.072-1.034)

0.460 (0.039-5.418)

  1. OR = odds ratio; 95% CI = odds ratio confidence interval. ORs are adjusted for age and sex; * D1 = points (< 1.5 cm], D2 = nodular dimensions [1.5 - 3 cm] & parenchymal dimensions (> 3 cm), D3 = confluent dimensions, D4 = non confluent dimensions; * p-value < 0.05 compared with the reference group Q1; ** N = number of samples = 96.